Monitor the pace of ATM sales and any reverse stock split announcement to cure the Nasdaq bid-price deficiency before Jan 4, 2027. Watch for CSRC filing developments and any revenue updates from the AI compute business.
Price Chart
Executive Summary
Quanome Technologies filed a 424B5 prospectus supplement for an at-the-market (ATM) offering of up to $9.75 million in common stock through Maxim Group LLC, with a 3% commission. The company is a micro-cap Nevada holding company with PRC pharmaceutical distribution operations, recently pivoting to AI compute and quantum tech with no revenue from those segments. The stock trades at $0.474, well below the $1.00 Nasdaq minimum bid, and faces a delisting deadline of January 4, 2027. The ATM signals potential dilution and capital needs, while the Baby Shelf Limitation caps primary offerings at ~$9.75M per 12 months based on the $29.3M public float.
Key Facts
- ATM offering of up to $9,754,475 in common stock via Maxim Group LLC at up to 3% commission.
- Stock price $0.474 as of Oct 20, 2026, below Nasdaq $1.00 minimum bid; second compliance period ends Jan 4, 2027.
- Net tangible book value $6.73M ($0.20/share); after full ATM sale, pro forma $15.98M ($0.29/share), dilution of $0.18/share to new investors.
- 34,427,559 shares outstanding; up to 20,579,061 new shares at $0.474; 595,909 warrants outstanding.
- Baby Shelf Limitation: max ~$9.75M in primary offerings per 12 months given ~$29.3M public float.
- No revenue from AI compute or quantum segments; pharmaceutical distribution is primary revenue source.
- PRC operations subject to CSRC filing uncertainty and regulatory risks.
Financial Impact
Up to $9.75M gross proceeds from ATM; net proceeds after ~3% commission and ~$204K expenses could be ~$9.3M. Immediate dilution of $0.18/share to new investors.
Risk Factors
- Nasdaq delisting risk if bid price not cured by Jan 4, 2027.
- Potential CSRC filing requirements could delay or limit future capital raises.
- Dilution from ATM sales and outstanding warrants.
- No revenue from new AI/quantum segments; execution risk in pivoting from pharma distribution.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-111342 |
| Document: 0001213900-26-111342-index-headers.html | 0001213900-26-111342 |
| Document: 0001213900-26-111342-index.html | 0001213900-26-111342 |
| Document: 0001213900-26-111342.txt | 0001213900-26-111342 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $0.4427 $0.4097 | ▲ +7.45% | ▲ +6.93% | $0.3760 (+15.07%) |
Oct 21, 2026 6d ago | 424B5 | $0.4427 $0.4097 | ▲ +7.45% | ▲ +6.93% | $0.3760 (+15.07%) |
Oct 19, 2026 8d ago | EFFECT | $0.5356 $0.4740 | ▲ +11.50% | ▲ +11.84% | $0.3760 (+29.80%) |
Oct 5, 2026 22d ago | 8-K | $0.5790 $0.5220 | ▼ −9.84% | ▼ −10.39% | $0.3760 (−35.06%) |
Oct 1, 2026 26d ago | S-3/A | $0.5382 $0.5600 | ▲ +4.05% | ▲ +3.31% | $0.3760 (−30.14%) |
Oct 1, 2026 26d ago | Press Release | $0.5382 $0.5600 | ▲ +4.05% | ▲ +3.31% | $0.3760 (−30.14%) |
Sep 23, 2026 4w ago | 8-K | $0.8390 $0.8047 | ▼ −4.09% | ▼ −4.01% | $0.3760 (−55.18%) |
Sep 21, 2026 5w ago | 8-K | $0.8509 $0.8390 | ▼ −1.40% | ▼ −0.68% | $0.3760 (−55.81%) |
Sep 2, 2026 7w ago | S-3/A | $0.3280 $0.3241 | ▲ +1.19% | ▲ +2.24% | $0.3760 (−14.63%) |
Aug 20, 2026 9w ago | 8-K | $0.3405 $0.3294 | ▼ −3.26% | ▼ −3.67% | $0.3760 (+10.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers